Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio

► Clinical studies support the role of neoadjuvant cisplatin in head and neck cancer. ► Chemo-toxicity remains a limiting factor in cisplatin-based treatments. ► A model is presented on a novel cisplatin regimen as induction therapy. ► It is suggested that third-daily cisplatin improves normal tissue tolerance. ► Optimal tumour control implies no gap between induction and curative treatment.